Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO

Booking.com

Cantargia AB today announces that the abstract of the upcoming oral presentation of CAN04 phase I clinical data at the 2019 ASCO Annual Meeting is published on the conference website. The abstract reports available data on the 22 patients in the phase I trial based on the interim analysis performed in February 2019. These data show that the safety profile of CAN04 was good and that CAN04 treatment led to a decrease of the biomarkers IL-6 and CRP already after two weeks of therapy. Nine patients had stable disease as determined by irRC after eight weeks follow up. One patient with pancreatic

Source: Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO

Booking.com
Booking.com

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.